Psychotherapy is a collaborative treatment method used by psychologists to help people overcome various mental illnesses and emotional difficulties. Psychotherapy aims to improve an individual’s well-being and mental health by eliminating or controlling troubling symptoms. A psychotherapist addresses different types of mental, emotional, and behavioral problems such as troublesome phobia, compulsive disorders, and trauma, grief caused by death of loved ones, depression, anxiety, and medical illness. Many different types of psychotherapy techniques have been developed as per the need and indication of the patients. Psychotherapeutic drugs are also being used in combination with other techniques, which are found to be more effective than the use of a single technique. Psychotherapeutic drugs are used to treat several types of mental disorders such as schizophrenia, bipolar disorder, anxiety, and depression. Several types of psychotherapeutic drugs are available in the market for the treatment of severe mental illnesses and behavioral disorders. Majority of drug class used for the treatment of mental disorders include antidepressant, antipsychotics, and psychotherapeutic combination drugs.
High prevalence of mental disorders and depression globally, increase in risk of depression owing to poverty, unemployment, death of loved ones, or relationship problems are the key factors driving the global psychotherapeutic drugs market. According to the World Health Organization, over 300 million people, nearly 4.4% of the global population, suffered from depression in 2015. Additionally, the estimated number of people living with depression has increased by 18.4% from 2005 to 2015. Introduction of new psychotherapeutic drugs in the market, owing to the increase in R&D investment budgets, demand for cost-effective antipsychotic drugs, and therapeutic application of psychotherapeutic drugs are likely to boost demand for psychotherapeutic drugs during the forecast period. However, side effects such as drowsiness, insomnia, and blurred vision caused by antipsychotic drugs are likely to restrain the market during the forecast period. Moreover, patent expiry of top branded products is projected to open a window for the generic drugs market in the near future.
The global psychotherapeutic drugs market can be broadly segmented based on drug class, application, distribution channel, and region. In terms of drugs class, the market can be segmented into antipsychotic drugs, antidepressants, and psychotherapeutic combinations. Antipsychotic drugs are used to treat delusions, hallucinations, paranoia, and confusion. These are also used to treat schizophrenia, severe depression, severe anxiety, and to some extent bipolar disorders. The antipsychotic drugs segment accounted for the largest market share in 2016 and the trend is likely to continue from 2017 to 2025. The segment can be sub-segmented into thioxanthenes, atypical antipsychotics, phenothiazine antipsychotics, and miscellaneous antipsychotic agents. The antidepressants segment can be further divided into selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tetracyclic antidepressants, tricyclic antidepressants, and miscellaneous antidepressants. Based on application, the market can be segmented into schizophrenia, dementia, bipolar, and unipolar depression. In terms of distribution channel, the psychotherapeutic drugs market can be categorized into hospital pharmacy, retail pharmacy, and online pharmacy.
Geographically, the global psychotherapeutic drugs market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global psychotherapeutic drugs market in 2016. High prevalence of depression and mental disorders, high per capita health care expenditure, and favorable medical reimbursement policies are the key factors likely to contribute to the growth of the psychotherapeutic drugs market in North America during the forecast period. According to the Anxiety and Depression Association of America, over 18.1% of the population of the U.S. are diagnosed with mental disorders each year. Europe was the second leading market for psychotherapeutic drugs in 2016. The market in Asia Pacific is projected to expand at a rapid pace during the forecast period owing to rise in health care expenditure, easy access and availability of medication, and increase in awareness about mental disorders.
Key players operating in the global psychotherapeutic drugs market are Eli Lilly & Co., Johnson & Johnson, Pfizer, Inc., Bristol-Myers Squibb Company, Allergan, GlaxoSmithKline plc, AstraZeneca plc, and Astellas Pharma, Inc., among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.